This feature requires the newest version of Flash. You can download it here.
In This Article

Heart Failure and Devices at TCT

Hello.This is Ileana Piña. I'm Associate Chief of Cardiology at Montefiore Medical Center in the Bronx, and this is my blog. I talk to you very often from different meetings. Today I am at the Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco. For those of you who may be unfamiliar with this meeting, it is a high-energy meeting with a lot of interventional cardiologists. You may ask, "So, what are you doing there with heart failure?" Well, for the past 7 years, Daniel Burkhoff, JoAnn Lindenfeld, and I have chaired an entire day of heart failure and devices.

Why would heart failure have anything to do with devices? We know about cardiac resynchronization therapy, pacemakers, and defibrillators, but there is a lot more. The exciting thing about this meeting is that we get to bring sponsors in to talk about innovative ideas. We hear about things that are happening in Europe and abroad that may not have come to the United States yet.

We started out with a colleague of ours, Dr. Filippatos from Greece, who talked to us about the landscape of heart failure right now. As many of you know, we have not had a blockbuster drug recently. Certainly there are some drugs that have been approved in Europe that have not come to the United States, even though I hear that some studies are planned. We have drugs like relaxin, which may have some promising data with 48-hour improvement in dyspnea and a very intriguing reduction in mortality at 6 months.[1]


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.